Viktor H. Koelzer

List of Publications by Year
in descending order

88 papers	4,694 citations	101543 36 h-index	114465 63 g-index
106 all docs	106 docs citations	106 times ranked	9678 citing authors

#	Article	IF	Citations
1	Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study. Journal of Immunotherapy, 2022, 45, 35-42.	2.4	3
2	Update on the current opinion, status and future development of digital pathology in Switzerland in light of COVID-19. Journal of Clinical Pathology, 2022, 75, 687-689.	2.0	12
3	miRâ€579â€3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3â€Kinaseâ€“Protein Kinase B Pathway in Chronically Inflamed Liver. Hepatology Communications, 2022, 6, 1467-1481.	4.3	8
4	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	12.8	47
5	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. American Journal of Human Genetics, 2022, 109, 953-960.	6.2	23
6	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	16.0	8
7	Towards a national strategy for digital pathology in Switzerland. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 647-652.	2.8	7
8	Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. Clinical Cancer Research, 2022, 28, 4056-4069.	7.0	14
9	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut, 2021, 70, 544-554.	12.1	148
10	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 288-300.	7.0	13
11	Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma. European Urology Focus, 2021, 7, 152-162.	3.1	34
12	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell, 2021, 39, 288-293.	16.8	71
13	Oncogenic BRAF, unrestrained by TGFÎ²-receptor signalling, drives right-sided colonic tumorigenesis. Nature Communications, 2021, 12, 3464.	12.8	33
14	Bone Morphogenetic Protein Pathway Antagonism by Grem1 Regulates Epithelial Cell Fate in Intestinal Regeneration. Gastroenterology, 2021, 161, 239-254.e9.	1.3	25
15	Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. Laboratory Investigation, 2021, 101, 1561-1570.	3.7	15
16	Stromal composition predicts recurrence of early rectal cancer after local excision. Histopathology, 2021, 79, 947-956.	2.9	8
17	Towards computationally efficient prediction of molecular signatures from routine histology images. The Lancet Digital Health, 2021, 3, e752-e753.	12.3	7
18	Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. Gut, 2020, 69, 1092-1103.	12.1	52

#	Article	IF	Citations
19	Two distinct immunopathological profiles in autopsy lungs of COVID-19. Nature Communications, 2020, 11, 5086.	12.8	230
20	The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer. Clinical Cancer Research, 2020, 26, 4313-4325.	7.0	22
21	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	3.4	45
22	Single-Cell Quantification of mRNA Expression in The Human Brain. Scientific Reports, 2019, 9, 12353.	3.3	39
23	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nature Immunology, 2019, 20, 206-217.	14.5	51
24	Precision immunoprofiling by image analysis and artificial intelligence. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 511-522.	2.8	101
25	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. Clinical Colorectal Cancer, 2019, 18, e20-e38.	2.3	62
26	Abstract B050: Identification of PD-1T TILs and CXCL13 as determinants for response to anti-PD-1 treatment using human tumor explants. , 2019, , .		0
27	Abstract 4446: Assessment of tissue composition with digital pathology in colorectal cancer. , 2019, , .		3
28	Digital image analysis improves precision of <scp>PD</scp>â€Ł1 scoring in cutaneous melanoma. Histopathology, 2018, 73, 397-406.	2.9	54
29	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 2018, 67, 179-193.	12.1	73
30	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. OncoImmunology, 2018, 7, e1386362.	4.6	62
31	Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunology, Immunotherapy, 2018, 67, 39-45.	4.2	45
32	The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution, 2018, 2, 1661-1672.	7.8	99
33	A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nature Medicine, 2018, 24, 994-1004.	30.7	783
34	Association of genetic variations within the PD-L2 immune checkpoint gene with outcome in stage II and III colon cancer.. Journal of Clinical Oncology, 2018, 36, 626-626.	1.6	0
35	Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer. Histopathology, 2017, 70, 1044-1051.	2.9	32
36	DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 341-346.	2.8	14

#	Article	IF	Citations
37	Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. Neoplasia, 2017, 19, 196-206.	5.3	22
38	Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. OncoImmunology, 2017, 6, e1288330.	4.6	11
39	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. OncoImmunology, 2017, 6, e1342918.	4.6	90
40	Cytokeratinâ€based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience. Journal of Pathology: Clinical Research, 2017, 3, 171-178.	3.0	30
41	The ESRP1-GPR137 axis contributes to intestinal pathogenesis. ELife, 2017, 6, .	6.0	24
42	Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome. Frontiers in Oncology, 2016, 6, 252.	2.8	5
43	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitorsâ€”an autopsy study. , 2016, 4, 13.		162
44	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	8.1	227
45	Groverâ€™s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27
46	Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome. OncoImmunology, 2016, 5, e1106677.	4.6	99
47	Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas. Human Pathology, 2016, 52, 1-8.	2.0	31
48	Tumor budding in colorectal cancerâ€”ready for diagnostic practice?. Human Pathology, 2016, 47, 4-19.	2.0	186
49	The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. OncoImmunology, 2016, 5, e1062966.	4.6	80
50	Abstract 4135: A signature of rejection in colorectal cancer: immune markers and their epigenetic regulation. , 2016, , .		1
51	Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer. Journal of Translational Medicine, 2015, 13, 279.	4.4	47
52	Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 485-493.	2.8	94
53	Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin. Histopathology, 2015, 67, 464-473.	2.9	19
54	Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study. BMC Cancer, 2015, 15, 160.	2.6	48

#	Article	IF	Citations
55	Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome. Translational Research, 2015, 166, 207-217.	5.0	43
56	Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression. Cancer Research, 2015, 75, 4483-4493.	0.9	59
57	Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers. Human Pathology, 2015, 46, 1573-1581.	2.0	36
58	Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells. Histopathology, 2015, 66, 715-725.	2.9	20
59	TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget, 2015, 6, 874-885.	1.8	64
60	Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma. Oncotarget, 2015, 6, 4190-4201.	1.8	52
61	DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells. Oncotarget, 2015, 6, 36774-36788.	1.8	14
62	VE1 immunohistochemistry predictsBRAFV600E mutation status and clinical outcome in colorectal cancer. Oncotarget, 2015, 6, 41453-41463.	1.8	22
63	Abstract 4053: Misregulation of dicer miRNA processing correlates with antigen presentation and survival in colorectal cancer. , 2015, , .		0
64	Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. British Journal of Cancer, 2014, 110, 1008-1013.	6.4	69
65	A simple Bakerâ€™s cyst? Tocilizumab remits paraneoplastic signs and controls growth of IL-6-producing angiomatoid malignant fibrous histiocytoma. Rheumatology, 2014, 53, 1350-1352.	1.9	9
66	Tumor Budding in Upper Gastrointestinal Carcinomas. Frontiers in Oncology, 2014, 4, 216.	2.8	37
67	The Tumor Border Configuration of Colorectal Cancer as a Histomorphological Prognostic Indicator. Frontiers in Oncology, 2014, 4, 29.	2.8	48
68	The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology, 2014, 64, 577-584.	2.9	49
69	Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. International Journal of Cancer, 2014, 134, 2342-2351.	5.1	51
70	CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. Journal of Translational Medicine, 2014, 12, 81.	4.4	51
71	Tumor budding in the clinical management of colon and rectal cancer. Colorectal Cancer, 2014, 3, 387-403.	0.8	4
72	Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients. Oncotarget, 2014, 5, 4671-4682.	1.8	10

#	Article	IF	Citations
73	A Modular Approach to Suppression Assays: TLR Ligands, Conditioned Medium, and Viral Infection. Methods in Molecular Biology, 2014, 1169, 107-120.	0.9	0
74	Abstract 34: The receptor for hyaluronan acid mediator motility (RHAMM, CD168) expression in EMT-like cancer cells is a predictor of tumor progression in colorectal cancer. , 2014, , .		0
75	Abstract 3825: High DAPK expression is correlated with worse prognosis in colorectal cancer patients. , 2014, , .		0
76	Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. Journal of Translational Medicine, 2013, 11, 104.	4.4	65
77	Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Human Pathology, 2013, 44, 697-705.	2.0	109
78	Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. British Journal of Cancer, 2013, 108, 2088-2096.	6.4	36
79	Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Modern Pathology, 2013, 26, 295-301.	5.5	114
80	Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. Frontiers in Oncology, 2013, 3, 265.	2.8	29
81	T-cell infiltrates and tumor budding: promising prognostic factors in the tumor microenvironment of colorectal cancer. Colorectal Cancer, 2013, 2, 173-176.	0.8	0
82	Abstract 4987: Immunoscore of CD8/CD45RO in pre-operative biopsy specimens predicts TNM-stage in primary colorectal cancer.. , 2013, , .		0
83	Abstract 4694: Nuclear expression of IL23p19 shows indolent tumor features and favorable outcome in patients with colorectal cancer.. , 2013, , .		0
84	Prognostic impact of Î²-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. Journal of Clinical Pathology, 2012, 65, 996-1002.	2.0	36
85	Mo1634 Keeping Check on Tumor-Host Interaction: Triple Positive MHC-I/CD8/Tia1 Expression Improves Outcome in Patients With Colorectal Cancer. Gastroenterology, 2012, 142, S-646.	1.3	0
86	CD103 is a hallmark of tumorâ€infiltrating regulatory T cells. International Journal of Cancer, 2011, 129, 2417-2426.	5.1	104
87	Immunostimulatory RNA Blocks Suppression by Regulatory T Cells. Journal of Immunology, 2010, 184, 939-946.	0.8	55
88	Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo. Cancer Immunology, Immunotherapy, 2009, 58, 901-913.	4.2	15